JP2011526886A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526886A5
JP2011526886A5 JP2011516197A JP2011516197A JP2011526886A5 JP 2011526886 A5 JP2011526886 A5 JP 2011526886A5 JP 2011516197 A JP2011516197 A JP 2011516197A JP 2011516197 A JP2011516197 A JP 2011516197A JP 2011526886 A5 JP2011526886 A5 JP 2011526886A5
Authority
JP
Japan
Prior art keywords
seq
formula
group
asn
b31lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011516197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526886A (ja
Filing date
Publication date
Priority claimed from PL385586A external-priority patent/PL219335B1/pl
Application filed filed Critical
Publication of JP2011526886A publication Critical patent/JP2011526886A/ja
Publication of JP2011526886A5 publication Critical patent/JP2011526886A5/ja
Pending legal-status Critical Current

Links

JP2011516197A 2008-07-04 2009-07-04 持効型活性を有する新規インスリン類似体 Pending JP2011526886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPL385586 2008-07-04
PL385586A PL219335B1 (pl) 2008-07-04 2008-07-04 Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
PCT/PL2009/050010 WO2010002283A2 (en) 2008-07-04 2009-07-04 New insulin analogues of prolonged activity

Publications (2)

Publication Number Publication Date
JP2011526886A JP2011526886A (ja) 2011-10-20
JP2011526886A5 true JP2011526886A5 (enExample) 2012-09-20

Family

ID=41130257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516197A Pending JP2011526886A (ja) 2008-07-04 2009-07-04 持効型活性を有する新規インスリン類似体

Country Status (8)

Country Link
US (2) US8618048B2 (enExample)
EP (2) EP2371853B1 (enExample)
JP (1) JP2011526886A (enExample)
CN (1) CN102083855A (enExample)
CA (1) CA2729938C (enExample)
EA (1) EA023559B1 (enExample)
PL (2) PL219335B1 (enExample)
WO (1) WO2010002283A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
WO2012115638A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
PL222975B1 (pl) * 2012-05-23 2016-09-30 Inst Biotechnologii I Antybiotyków Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny
US9624287B2 (en) 2012-07-17 2017-04-18 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
DK2877200T3 (da) * 2012-07-17 2019-08-12 Univ Case Western Reserve O-bundne carbonhydratmodificerede insulinanaloger
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP2016505627A (ja) * 2013-01-15 2016-02-25 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 治療剤、組成物、および血糖コントロールのための方法
WO2014122653A1 (en) * 2013-02-07 2014-08-14 Valin Technologies Ltd. Process for preparing insulin
CN103981243A (zh) * 2013-02-07 2014-08-13 华凌科技有限公司 胰岛素的制备方法
CN103981242A (zh) * 2013-02-07 2014-08-13 华凌科技有限公司 胰岛素的制备方法
WO2014122651A1 (en) * 2013-02-07 2014-08-14 Valin Technologies Ltd. Process for preparing insulin
SI3057984T1 (sl) 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
PL239062B1 (pl) * 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
CA3294636A1 (en) * 2016-11-21 2026-02-10 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
KR102666154B1 (ko) * 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
SG11202106168VA (en) * 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
EP4048686A4 (en) * 2019-10-24 2024-01-03 University Of Utah Research Foundation NEW MINI INSULIN WITH EXTENDED C-TERMINAL A-CHAIN

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US5434247A (en) * 1986-10-10 1995-07-18 Board Of Regents, The University Of Texas System Peptides for inducing monocyte cytotoxicity in diagnostics
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
SG44748A1 (en) * 1991-12-18 1997-12-19 Hoechst Ag Process for obtaining insulin-containing solutions
HU220357B (hu) 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
DE19652713C2 (de) 1996-12-18 2001-11-22 Aventis Pharma Gmbh Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
ES2313018T3 (es) * 2003-06-17 2009-03-01 Sembiosys Genetics Inc. Procedimiento de produccion de insulina en plantas.
PL213561B1 (pl) 2004-01-09 2013-03-29 Inst Biotechnologii I Antybiotykow Sposób otrzymywania plazmidu, plazmid oraz zastosowania
US7893197B2 (en) * 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
EP2801366A3 (en) * 2004-09-02 2015-04-29 Cognosci, Inc. Improved apo E analogs and methods for their use
PL373543A1 (pl) * 2005-03-10 2006-09-18 Instytut Biotechnologii i Antybiotyków Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy
EP2371850A3 (en) * 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP1996709A2 (en) * 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP2049149B1 (en) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins

Similar Documents

Publication Publication Date Title
JP2011526886A5 (enExample)
CN103649115B (zh) 多肽
ES2662501T3 (es) Derivados de amilina
KR102092206B1 (ko) 장기-작용성 glp-1/글루카곤 수용체 작용제
CA2729938A1 (en) New insulin analogues of prolonged activity
JP2016512213A5 (enExample)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2013518115A5 (enExample)
TW201716431A (zh) 升糖素及ｇｌｐ－１共激動劑化合物
JP2011524420A5 (enExample)
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2010529957A5 (enExample)
JP2018505146A5 (enExample)
JP2007523881A5 (enExample)
JP2005530732A5 (enExample)
WO2010111617A4 (en) Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CN104395338A (zh) 人胰岛淀粉样多肽类似物
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2020507623A5 (enExample)
DK3074032T3 (en) Fatty acid derivatives of dimeric PSD-95 inhibitors
JP2016510728A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2006506942A5 (enExample)
US20180009849A1 (en) Ghrelin analogues
JP2011518176A5 (enExample)